EUS-FNA with rescue fluorescence in situ hybridization for the diagnosis of pancreatic carcinoma in patients with inconclusive on-site cytopathology results

Nisa Kubiliun, Afonso Ribeiro, Yao-Shan Fan, Caio Max Rocha-Lima, Danny Sleeman, Jaime R Merchan, Jamie S Barkin, Joe Levi

Research output: Contribution to journalArticle

30 Citations (Scopus)

Abstract

Background: Detection of chromosomal abnormalities by fluorescence in situ hybridization (FISH) analysis has not been well-studied in FNA samples of pancreatic masses. Selective use of FISH in patients with inconclusive on-site cytopathology results may improve the sensitivity of EUS for malignancy. Objective: To determine the sensitivity and specificity of FISH analysis in patients with inconclusive on-site cytopathology results. Design: Consecutive patients with suspected pancreatic malignancy, nonrandomized cohort study. Final diagnosis was based on either surgical biopsy or disease progression on extended follow-up or death. Setting: Academic center, tertiary-care referral cancer center. Patients: A total of 212 EUS examinations were performed in 206 patients for solid pancreatic lesions over a 24-month period (January 2009-December 2010). FISH analysis was done for 69 patients with inconclusive or nonavailable on-site cytology results. Intervention: EUS-guided FNA (EUS-FNA) of solid pancreatic masses with cytology and FISH analysis for polysomy of chromosomes 3, 7, and 17 and deletion of 9p21. Main Outcome Measurements: Sensitivity/specificity of cytology, FISH, and a composite of cytology and FISH. Results: Patients with positive on-site cytology (110), neuroendocrine tumors (22), insufficient follow-up (1), FISH not obtained (3), and renal cancer with pancreatic metastasis (1) were excluded. Sixty-nine patients comprised the study cohort, 54 with malignancy and 15 with benign disease. Sensitivity for malignancy of cytology, FISH analysis, and the combination were 61%, 74%, and 85%, respectively (P =.009). FISH detected an additional 13 cases of pancreatic adenocarcinoma missed by cytology. There was no false-positive FISH analysis in 15 patients with benign disease. No major complications occurred from EUS-FNA. Limitations: Single center, selected patients underwent FISH analysis, limited number of patients with benign disease. Conclusion: In patients with suspected pancreatic cancer, FISH analysis can detect additional cases missed by cytology without compromising specificity. FISH analysis to detect polysomy of chromosomes 3, 7, and 17 and deletion of 9p21 should be considered when cytology is negative for malignancy in patients with a known pancreatic mass.

Original languageEnglish
Pages (from-to)541-547
Number of pages7
JournalGastrointestinal Endoscopy
Volume74
Issue number3
DOIs
StatePublished - Sep 1 2011

Fingerprint

Endoscopic Ultrasound-Guided Fine Needle Aspiration
Fluorescence In Situ Hybridization
Cell Biology
Neoplasms
Chromosomes, Human, Pair 17
Chromosomes, Human, Pair 3
Chromosomes, Human, Pair 7
Pancreatic Carcinoma
Tertiary Care Centers
Cohort Studies
Sensitivity and Specificity
Neuroendocrine Tumors
Kidney Neoplasms
Pancreatic Neoplasms

ASJC Scopus subject areas

  • Gastroenterology
  • Radiology Nuclear Medicine and imaging

Cite this

EUS-FNA with rescue fluorescence in situ hybridization for the diagnosis of pancreatic carcinoma in patients with inconclusive on-site cytopathology results. / Kubiliun, Nisa; Ribeiro, Afonso; Fan, Yao-Shan; Rocha-Lima, Caio Max; Sleeman, Danny; Merchan, Jaime R; Barkin, Jamie S; Levi, Joe.

In: Gastrointestinal Endoscopy, Vol. 74, No. 3, 01.09.2011, p. 541-547.

Research output: Contribution to journalArticle

@article{cd631f1c4c144b3da917b355ed3cd03c,
title = "EUS-FNA with rescue fluorescence in situ hybridization for the diagnosis of pancreatic carcinoma in patients with inconclusive on-site cytopathology results",
abstract = "Background: Detection of chromosomal abnormalities by fluorescence in situ hybridization (FISH) analysis has not been well-studied in FNA samples of pancreatic masses. Selective use of FISH in patients with inconclusive on-site cytopathology results may improve the sensitivity of EUS for malignancy. Objective: To determine the sensitivity and specificity of FISH analysis in patients with inconclusive on-site cytopathology results. Design: Consecutive patients with suspected pancreatic malignancy, nonrandomized cohort study. Final diagnosis was based on either surgical biopsy or disease progression on extended follow-up or death. Setting: Academic center, tertiary-care referral cancer center. Patients: A total of 212 EUS examinations were performed in 206 patients for solid pancreatic lesions over a 24-month period (January 2009-December 2010). FISH analysis was done for 69 patients with inconclusive or nonavailable on-site cytology results. Intervention: EUS-guided FNA (EUS-FNA) of solid pancreatic masses with cytology and FISH analysis for polysomy of chromosomes 3, 7, and 17 and deletion of 9p21. Main Outcome Measurements: Sensitivity/specificity of cytology, FISH, and a composite of cytology and FISH. Results: Patients with positive on-site cytology (110), neuroendocrine tumors (22), insufficient follow-up (1), FISH not obtained (3), and renal cancer with pancreatic metastasis (1) were excluded. Sixty-nine patients comprised the study cohort, 54 with malignancy and 15 with benign disease. Sensitivity for malignancy of cytology, FISH analysis, and the combination were 61{\%}, 74{\%}, and 85{\%}, respectively (P =.009). FISH detected an additional 13 cases of pancreatic adenocarcinoma missed by cytology. There was no false-positive FISH analysis in 15 patients with benign disease. No major complications occurred from EUS-FNA. Limitations: Single center, selected patients underwent FISH analysis, limited number of patients with benign disease. Conclusion: In patients with suspected pancreatic cancer, FISH analysis can detect additional cases missed by cytology without compromising specificity. FISH analysis to detect polysomy of chromosomes 3, 7, and 17 and deletion of 9p21 should be considered when cytology is negative for malignancy in patients with a known pancreatic mass.",
author = "Nisa Kubiliun and Afonso Ribeiro and Yao-Shan Fan and Rocha-Lima, {Caio Max} and Danny Sleeman and Merchan, {Jaime R} and Barkin, {Jamie S} and Joe Levi",
year = "2011",
month = "9",
day = "1",
doi = "10.1016/j.gie.2011.04.043",
language = "English",
volume = "74",
pages = "541--547",
journal = "Gastrointestinal Endoscopy",
issn = "0016-5107",
publisher = "Mosby Inc.",
number = "3",

}

TY - JOUR

T1 - EUS-FNA with rescue fluorescence in situ hybridization for the diagnosis of pancreatic carcinoma in patients with inconclusive on-site cytopathology results

AU - Kubiliun, Nisa

AU - Ribeiro, Afonso

AU - Fan, Yao-Shan

AU - Rocha-Lima, Caio Max

AU - Sleeman, Danny

AU - Merchan, Jaime R

AU - Barkin, Jamie S

AU - Levi, Joe

PY - 2011/9/1

Y1 - 2011/9/1

N2 - Background: Detection of chromosomal abnormalities by fluorescence in situ hybridization (FISH) analysis has not been well-studied in FNA samples of pancreatic masses. Selective use of FISH in patients with inconclusive on-site cytopathology results may improve the sensitivity of EUS for malignancy. Objective: To determine the sensitivity and specificity of FISH analysis in patients with inconclusive on-site cytopathology results. Design: Consecutive patients with suspected pancreatic malignancy, nonrandomized cohort study. Final diagnosis was based on either surgical biopsy or disease progression on extended follow-up or death. Setting: Academic center, tertiary-care referral cancer center. Patients: A total of 212 EUS examinations were performed in 206 patients for solid pancreatic lesions over a 24-month period (January 2009-December 2010). FISH analysis was done for 69 patients with inconclusive or nonavailable on-site cytology results. Intervention: EUS-guided FNA (EUS-FNA) of solid pancreatic masses with cytology and FISH analysis for polysomy of chromosomes 3, 7, and 17 and deletion of 9p21. Main Outcome Measurements: Sensitivity/specificity of cytology, FISH, and a composite of cytology and FISH. Results: Patients with positive on-site cytology (110), neuroendocrine tumors (22), insufficient follow-up (1), FISH not obtained (3), and renal cancer with pancreatic metastasis (1) were excluded. Sixty-nine patients comprised the study cohort, 54 with malignancy and 15 with benign disease. Sensitivity for malignancy of cytology, FISH analysis, and the combination were 61%, 74%, and 85%, respectively (P =.009). FISH detected an additional 13 cases of pancreatic adenocarcinoma missed by cytology. There was no false-positive FISH analysis in 15 patients with benign disease. No major complications occurred from EUS-FNA. Limitations: Single center, selected patients underwent FISH analysis, limited number of patients with benign disease. Conclusion: In patients with suspected pancreatic cancer, FISH analysis can detect additional cases missed by cytology without compromising specificity. FISH analysis to detect polysomy of chromosomes 3, 7, and 17 and deletion of 9p21 should be considered when cytology is negative for malignancy in patients with a known pancreatic mass.

AB - Background: Detection of chromosomal abnormalities by fluorescence in situ hybridization (FISH) analysis has not been well-studied in FNA samples of pancreatic masses. Selective use of FISH in patients with inconclusive on-site cytopathology results may improve the sensitivity of EUS for malignancy. Objective: To determine the sensitivity and specificity of FISH analysis in patients with inconclusive on-site cytopathology results. Design: Consecutive patients with suspected pancreatic malignancy, nonrandomized cohort study. Final diagnosis was based on either surgical biopsy or disease progression on extended follow-up or death. Setting: Academic center, tertiary-care referral cancer center. Patients: A total of 212 EUS examinations were performed in 206 patients for solid pancreatic lesions over a 24-month period (January 2009-December 2010). FISH analysis was done for 69 patients with inconclusive or nonavailable on-site cytology results. Intervention: EUS-guided FNA (EUS-FNA) of solid pancreatic masses with cytology and FISH analysis for polysomy of chromosomes 3, 7, and 17 and deletion of 9p21. Main Outcome Measurements: Sensitivity/specificity of cytology, FISH, and a composite of cytology and FISH. Results: Patients with positive on-site cytology (110), neuroendocrine tumors (22), insufficient follow-up (1), FISH not obtained (3), and renal cancer with pancreatic metastasis (1) were excluded. Sixty-nine patients comprised the study cohort, 54 with malignancy and 15 with benign disease. Sensitivity for malignancy of cytology, FISH analysis, and the combination were 61%, 74%, and 85%, respectively (P =.009). FISH detected an additional 13 cases of pancreatic adenocarcinoma missed by cytology. There was no false-positive FISH analysis in 15 patients with benign disease. No major complications occurred from EUS-FNA. Limitations: Single center, selected patients underwent FISH analysis, limited number of patients with benign disease. Conclusion: In patients with suspected pancreatic cancer, FISH analysis can detect additional cases missed by cytology without compromising specificity. FISH analysis to detect polysomy of chromosomes 3, 7, and 17 and deletion of 9p21 should be considered when cytology is negative for malignancy in patients with a known pancreatic mass.

UR - http://www.scopus.com/inward/record.url?scp=80052271801&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80052271801&partnerID=8YFLogxK

U2 - 10.1016/j.gie.2011.04.043

DO - 10.1016/j.gie.2011.04.043

M3 - Article

VL - 74

SP - 541

EP - 547

JO - Gastrointestinal Endoscopy

JF - Gastrointestinal Endoscopy

SN - 0016-5107

IS - 3

ER -